Prognosis
Pfizer’s New Covid Shot Works Better Than Original Booster, Data Show
- Antibody levels lower against new strain versus original virus
- Analyst says protection from new shot may be too weak
This article is for subscribers only.
Pfizer Inc. released more data that its new Covid vaccine bolsters protective antibodies against the emerging omicron strains more than the original booster.
Pfizer and German vaccine partner BioNTech SE said Friday the bivalent booster may give better protection against the latest omicron strains, including the rapidly expanding BQ.1.1 strain. The results were similar to a study on people 55 years and older looking at other omicron variants released earlier this month.